
Full name:bluebird bio, Inc.;
Full Address:150 Second Street Cambridge, MA 02141 United States 339-499-9300 http://www.bluebirdbio.com;
Sector:Healthcare;
Industry:Biotechnology;
Market Car: 7.26B;

Description:
 bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing transformative gene therapies forsevere genetic diseases and cancer. Its product candidates include Lenti-D that is in phase II/III clinical studies forthe treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is infour clinical studies for the treatment of transfusion-dependent beta-thalassemia, and severe sickle cell disease. ThecompanyÂ’s lead product candidate is bb2121, a chimeric antigen receptor T cell product candidate that is in Phase I trialfor the treatment of relapsed/refractory multiple myeloma. bluebird bio, Inc. has a strategic collaboration withCelgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology; Kite Pharma, Inc.to develop and commercialize second generation T cell receptor (TCR) product candidates against an antigen related tocertain cancers associated with the human papilloma virus; and Medigene AG for the research and development of TCRproduct candidates directed against approximately four antigens for the treatment of cancer indications. The company wasformerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebirdbio, Inc. was founded in 1992 and is headquartered in Cambridge, Massachusetts.;

Fiscal Year:2016;
Total Revenue:6155;
Net Revenue:-263507;
Total Assets:1118122;

Fiscal Year:2015;
Total Revenue:14079;
Net Revenue:-166783;
Total Assets:1002337;

Fiscal Year:2014;
Total Revenue:25421;
Net Revenue:-48709;
Total Assets:556739;


